Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
FDA hands Crestor a fighting chance
In the battle of the cholesterol meds, Crestor just got a new weapon. The FDA approved AstraZeneca's application to market the drug not just for lowering cholesterol, but to treat hardening of the arteries, too. It's the first statin to win approval for that indication.
It's an important coup for AstraZeneca, which has been looking for an edge for Crestor--a late entry onto the statin field. As you know, those efforts were compromised earlier this week by research showing the drug didn't alleviate heart failure. And last week, AstraZeneca announced it was facing a generic challenge to Crestor's patents.
- check out the release from AstraZeneca
- read the report from The Times
Related Articles:
AZ's Crestor flubs key heart failure trial. Report
AZ hit with Crestor patent challenge. Report
Crestor less safe than competing statins. Report
Top 5 layoffs of 2007--AstraZeneca. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
